Global Information
회사소개 | 문의 | 비교리스트

세계의 순환종양세포(CTC) 시장 : 기술별, 용도별, 지역별 - 성장, 동향, 예측(2018-2023년)

Circulating Tumor Cells (CTC) Market - Growth, Trends, and Forecast (2019 - 2024)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2019년 05월 상품 코드 649744
페이지 정보 영문
US $ 4,250 ₩ 5,110,000 PDF (Single User License)
US $ 4,750 ₩ 5,711,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,215,000 PDF (Site License)
US $ 7,500 ₩ 9,018,000 PDF (Corporate License)

세계의 순환종양세포(CTC) 시장 : 기술별, 용도별, 지역별 - 성장, 동향, 예측(2018-2023년) Circulating Tumor Cells (CTC) Market - Growth, Trends, and Forecast (2019 - 2024)
발행일 : 2019년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 순환종양세포(CTC) 시장은 2018-2023년간 약 9.0%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 순환종양세포(CTC)는 순환기계 및 림프액계를 거쳐 체내를 순환하는 암세포를 가리킵니다. 암 유병률 상승, 동반진단(CDx) 및 예방의학 수요 증가에 의해 시장 성장이 촉진되고 있습니다.

세계의 순환종양세포(CTC: Circulating Tumor Cells) 시장을 조사했으며, 시장 개요, 기술·용도·지역별 시장 동향, 시장 규모 추이와 예측, 성장 촉진요인 및 저해요인, 시장 기회와 과제, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.


제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 영향요인

제5장 시장 개요

  • 현재의 시장 시나리오
  • Five Forces 분석
    • 구매자의 협상력
    • 공급 기업의 협상력
    • 신규 진출기업의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제6장 시장 역학

  • 시장 성장 촉진요인
    • 클러스터 칩 기술 발전
    • 생체의학 영상과 바이오엔지니어링 기술 진보
    • 예방의료 및 동반진단 수요 증가
    • 암 유병률 상승
  • 시장 성장 저해요인
    • 고액의 진단 비용에 관련된 CTC 검출 및 분석 기술의 과제
    • 첨단 CTC 기술에 대한 낮은 관심도와 이용 반감
  • 시장 기회
  • 주요 과제

제7장 세계의 순환종양세포(CTC) 시장 : 부문별

  • 기술별
    • CTC 농축법
    • CTC 검출법
  • 용도별
    • 상피간엽전환(EMT) 마커 개발
    • 종양 형성 연구
    • 암 줄기세포
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제8장 경쟁 구도

  • 인수합병 분석
  • 합의, 협업, 제휴
  • 신제품 출시

제9장 주요 기업 개요

  • Advanced Cell Diagnostics, Inc
  • ApoCell
  • Aviva Biosciences
  • Biocept Inc
  • CellTraffix Inc
  • Clearbridge Biomedics Pte Ltd
  • Creatv Microtech Inc
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • Qiagen

제10장 시장 전망

LSH 18.06.18

Market Overview

The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology, rising demand for preventive medicine and companion diagnostics, and growing prevalence of cancer.

The global cancer burden is increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers were the most common and contributed about 12.3% of the total number of new cases that were diagnosed in 2018. Almost half of the cancer prevalence occurs in Asia, and in Europe, one-quarter of the population is suffering from cancer. In the Americas, 21% of the population is suffering from cancer. The increasing cancer burden is due to a number of factors, including population growth and aging and the changing prevalence of certain causes of cancer linked to social and economic development. According to the WHO, in 2018, approximately 70% of the deaths in low and middle-income countries were due to cancer. With this growing burden, prevention of cancer is one of the most significant challenges. Furthermore, according to the Globocan Database, in 2018, it was estimated that the number of new cases would grow from 18.1 million to 29.4 million, between 2018 and 2040. Thus, the increasing prevalence of cancer is one of the major factors that are augmenting the growth of the market.

Scope of the Report

As per the scope of this report, circulating tumor cells (CTC) refer to the tumor cells that circulate inside the body through the blood circulatory system and lymphatic system. Factors, such as the high prevalence of cancer, advancements in biomedical imaging and bioengineering technology, and increased demand for preventive medicine, with the need for companion diagnostics, drive the circulating tumor cell market globally. The market is segmented by technology, application, and geography.

Key Market Trends

Negative Enrichment is the Segment by CTC Enrichment Methods is Expected to Dominate the Market

In case of the positive enrichment methods it cannot isolate CTCs depending on heterogeneous properties, but negative enrichment methods can isolate heterogeneous and intact CTCs by specifically eliminating blood cells. The rising prevalence of the various types of cancer is expected to drive the overall growth of the market. The analysis of circulating tumor cells is an increasing interest for monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs, and for research into the mechanisms of disease progression. In addition, negative enrichment has advantages over positive enrichment in isolating CTCs owing to which the market is expected to witness high growth over the forecast period.

North America is Expected to Dominate the Market

In 2018, as per the American Cancer Society, above 15.5% of Americans had a history of cancer by 2016, of which a majority have been diagnosed in the past two years. The highest number of new cases are being reported, such as respiratory system, breast, genital system, and urinary system, with about 1.7 million new cases being reported in 2018. Based on healthcare expenditure, the United States is among the major countries across the world, which spends about 17.1% of its total GDP on healthcare. The expenditure for cancer patients is mostly in breast, lung, and colon and rectum cancers. The United States has one of the highly successful products approved by the US Food and Drug Administration (FDA), CellSearch Circulating Tumor Cell Kit. The product has reimbursement facility through various public and private payers in several states of the country, such as Cigna Government Services, Noridian, and United HealthCare, amongst others. Several universities across the United States, have relied on CTCs applications to advance the practice of pathology and laboratory medicine. Thus, owing to the all above-mentioned factors the market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are Advanced Cell Diagnostics, Inc, Aviva Biosciences, Biocept Inc, Creatv Micro Tech, Inc., LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine formerly ApoCell, and Qiagen NV

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advancements in Biomedical Imaging and Bioengineering Technology
    • 4.2.2 Rising Demand for Preventive Medicine and Companion Diagnostics
    • 4.2.3 Growing Prevalence of Cancer
  • 4.3 Market Restraints
    • 4.3.1 Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis
    • 4.3.2 Lack of Awarness and Unwillingness for the Adoption of Advanced CTC Technologioes
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Technology
    • 5.1.1 CTC Enrichment Methods
      • Positive Enrichment
      • Negative Enrichment
      • Others
    • 5.1.2 CTC Detection Methods
      • Immunocytochemical Technology
      • Molecular (RNA) based Technology
      • Others
  • 5.2 By Application
    • 5.2.1 Multiple Chromosome Abnormalities
    • 5.2.2 RNA Profiling
    • 5.2.3 Protein Expression
    • 5.2.4 Cellular Communication
    • 5.2.5 Other
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Advanced Cell Diagnostics, Inc
    • 6.1.2 Aviva Biosciences
    • 6.1.3 Biocept Inc
    • 6.1.4 Creatv Micro Tech, Inc.
    • 6.1.5 LungLife AI, Inc.
    • 6.1.6 Menarini Silicon Biosystems
    • 6.1.7 Miltenyi Biotec
    • 6.1.8 Precision For Medicine, formerly ApoCell,
    • 6.1.9 Qiagen NV


Back to Top
전화 문의